Spyre Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Spyre Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $85.72 million for the year ending 2025.

  • Spyre Therapeutics, Inc. showed a decrease of -4.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
  • XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 13 years of available data (2013 to 2025), Spyre Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,764.7%.
  • Historical annual values: Fiscal year 2025: $85.72 million | Fiscal year 2024: $89.42 million | Fiscal year 2023: $188.89 million | Fiscal year 2022: $34.86 million | Fiscal year 2021: $15.14 million | Fiscal year 2020: $90.10 million | Fiscal year 2019: $19.25 million | Fiscal year 2018: $22.46 million | Fiscal year 2017: $12.82 million | Fiscal year 2016: $47.75 million | Fiscal year 2015: $29.29 million | Fiscal year 2014: $2.62 million | Fiscal year 2013: $4.60 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: